'Stop Ripping Us Off.' Senate Grills Novo Nordisk on High Prices of Weight Loss Drugs Wegovy and Ozempic in US.

Novo Nordisk CEO Lars Fruergaard Jørgensen faced Senate scrutiny over the high prices of Wegovy and Ozempic as U.S. demand surges. While Jørgensen did not commit to lowering prices, he was willing to work on policy solutions to reduce prescription drug costs. Sen. Bernie Sanders urged Novo Nordisk CEO Lars Fruergaard Jørgensen to reduce the high U.S. prices of Wegovy and Ozempic, stating, “Stop ripping us off” and calling for equal treatment for Americans. Lawmakers continue to pressure the pharmaceutical industry to cut prices amid growing healthcare costs.